West Pharmaceutical Services (WST) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential shareholder claims on behalf of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services" or the "Company") (WST) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

What's Being Investigated?

The investigation follows the filing of a securities class action complaint against the Company on May 5, 2025, which alleges that West Pharmaceutical Services and certain of its directors and officers failed to disclose significant and ongoing destocking in its High-Value Products portfolio despite public statements suggesting stable demand visibility. According to the lawsuit, West Pharmaceutical Services described SmartDose as a high-margin growth opportunity but failed to disclose that manufacturing inefficiencies made the product margin-dilutive. The complaint further alleges that management understated restructuring risks tied to continuous glucose monitoring partnerships. On February 13, 2025, the Company issued weak 2025 forecasts, citing the loss of two major manufacturing customers and confirming that SmartDose products would weigh on profit margins.

Market Reaction

Following these disclosures, West Pharmaceutical Services’ stock fell $123.17 per share, or approximately 38%, closing at $199.11 on February 13, 2025, resulting in significant harm to the Company.

What Shareholders Can Do?

If you have held West Pharmaceutical Services (WST) stock since at least February 2023, you may be able to seek corporate reforms, the return of funds back to the Company, and a court-approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions, and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.